In breast cancer, CD24−/CD44+ CSCs were evaluated by flow cytometry before and after treatment only in a neoadjuvant trial where, similar to our study, a proportion of patients showed no detectable CD24−/CD44+ at baseline [25]. The gene discussed is CD44; the disease is breast carcinoma.